Patient Care and Research

Section Menu  


ASTRO Guideline on Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma

Published: September-October 2022 (Web posted June 2022)

Read Full-Text Guideline

This new guideline addresses the management of adult patients with IDH-mutant grade 2 and grade 3 diffuse glioma (as defined by WHO 2021 classification) which includes astrocytoma, IDH-mutant, WHO grade 2; astrocytoma, IDH-mutant, WHO grade 3; oligodendroglioma, IDH-mutant, 1p/19q codeleted, WHO grade 2; and oligodendroglioma, IDH-mutant, 1p/19q codeleted, WHO grade 3.

Developed in collaboration with:

  • American Association of Neurological Surgeons/Congress of Neurological Surgeons
  • American Association of Neuropathologists
  • American Society of Clinical Oncology
  • Society for Neuro-Oncology

Endorsed by:

  • Society for Neuro-Oncology
  • Canadian Association of Radiation Oncology
  • European Society for Radiotherapy and Oncology
  • Royal Australian and New Zealand College of Radiologists


Copyright © 2024 American Society for Radiation Oncology